Sanofi Says Pfizer’s PCSK9 Phase III Plan Will Boost The New Drug Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi CEO Christopher Viehbacher seemed unperturbed by Pfizer’s ambitious PCSK9 Phase III development program, saying it will increase interest in the new drug class.